ASH 2018 dr. Peter Westerweel

ASH 2018 dr. Peter Westerweel, werkzaam in het Albert Schweitzer Ziekenhuis te Dordrecht

 

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a Gimema and HOVON Study
 

0718HEM1085464
×

Ask Speakers

×

Medical Information Request